Are you developing a future targeted therapy? Are you working on a hot yet challenging drug target? Our Challenging Target Award program is designed for life science startups to de-risk & accelerate top-in-class drug discovery programs.
We will provide exclusive access to our MICRO-TAG™ platform. We will work closely with you through discovery, validation and analysis of novel drug candidates to your desired drug target. Then assist in positioning this data for your investors and leadership.
About CellarisBio
CellarisBio is a drug discovery platform built for challenging drug targets. We employ cell target engagement to interrogate targets within their complex cellular milieu. We help build winning discovery programs from hit ID to lead optimization, by navigating chemical space, in-cell potency, selectivity and mechanism-of-action, ultimately accelerating them to IND.
The MICRO-TAG™ platform supports discovery and validation of inhibitors, allosteric binders, molecular glues, degraders and target stabilizers.
· Applicant is an incorporated life science company.
· Focus on small- and medium-size therapeutics.
· No previous purchase from CellarisBio is necessary to apply.
· Agnostic to location of applicants.
· CellarisBio does not put any claim on the generated data nor Intellectual Property of our applicants and winners.
· CDA will be signed with finalists.
· Purchase of any additional services from CellarisBio is not required.
· Award engagement varies anywhere from 1-24 months.
Read Terms of Award.
1st place: Credit of $35K + consultancy
2nd place: Credit of $25K + consultancy
3rd place: Credit of $15K + consultancy
Copyright © 2024 CellarisBio - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
Are you developing a future targeted therapy?
Are you working on a hot yet challenging drug target?
The Challenging Target Award program is designed for life science companies to de-risk & accelerate top-in-class drug discovery programs.